Mersana Therapeutics (NASDAQ: MRSN) is one of 287 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Mersana Therapeutics to related businesses based on the strength of its analyst recommendations, profitability, valuation, risk, institutional ownership, earnings and dividends.

Insider and Institutional Ownership

76.7% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares Mersana Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mersana Therapeutics N/A N/A N/A
Mersana Therapeutics Competitors -5,387.16% -160.69% -35.34%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Mersana Therapeutics and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mersana Therapeutics 0 0 4 0 3.00
Mersana Therapeutics Competitors 930 3372 11881 239 2.70

Mersana Therapeutics currently has a consensus price target of $23.67, suggesting a potential upside of 44.31%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.83%. Given Mersana Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Mersana Therapeutics is more favorable than its rivals.

Earnings & Valuation

This table compares Mersana Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mersana Therapeutics N/A N/A N/A
Mersana Therapeutics Competitors $290.27 million $35.99 million 54.67

Mersana Therapeutics’ rivals have higher revenue and earnings than Mersana Therapeutics.


Mersana Therapeutics beats its rivals on 7 of the 10 factors compared.

About Mersana Therapeutics

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with's FREE daily email newsletter.